A Single-arm, Multi-center, Prospective Clinical Study of Mitoxantrone Hydrochloride Liposome Injection-based CMOP±R Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma

The First Affiliated Hospital of Soochow University0 sites197 target enrollmentJuly 10, 2024

ConditionsNHL

InterventionsCMOP±R

Overview

Phase: Phase 2
Intervention: CMOP±R
Conditions: NHL
Sponsor: The First Affiliated Hospital of Soochow University
Enrollment: 197
Primary Endpoint: Complete Response Rate (CRR)
Status: Not yet recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This is a prospective, single arm, multicenter study to evaluate the safety and efficacy of CMOP±R in patients with newly diagnosed non-Hodgkin's lymphoma.

Detailed Description

This is a single-arm, open label, multi-center clinical study to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in combination with Cyclophosphamide, Vincristine, Prednisone and/or Rituximab(CMOP±R) in patients with newly diagnosed non-Hodgkin's lymphoma. Mitoxantrone hydrochloride liposome will be given on day 1 at dose of 18 mg/m2 and be combined with cyclophosphamide, vincristine, prednisone and/or Rituximab. Each cycle consists of 28 days. A maximum of 8 cycles(6×CMOP±R+2×R) of therapy are planned.

Registry

clinicaltrials.gov

Start Date

July 10, 2024

End Date

August 31, 2027

Last Updated

last year

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

The First Affiliated Hospital of Soochow University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients fully understand this study, voluntarily participate and sign the informed consent (ICF);
•Age: 18-75 years old;
•Expected survival time ≥ 3 months;
•Histopathologically diagnosed newly diagnosed non-Hodgkin's lymphoma;
•Must have at least one evaluable or measurable lesion that meets the Lugano 2014 criteria: lymph node lesions, measurable lymph nodes must have a long diameter \>1.5cm; non-lymph node lesions, measurable extranodal lesions must have a long diameter \>1.0cm;
•Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-
•Bone marrow function: Absolute neutrophil count (ANC) ≥1.5×10\^9/L, Platelet count (PLT) ≥75×10\^9/L, Hemoglobin(HB)≥ 80 g/L(Restriction may be relaxed in patients with bone marrow involvement, Absolute neutrophil count (ANC) ≥1.0×10\^9/L, Platelet count (PLT) ≥50×10\^9/L, Hemoglobin(HB)≥ 75g/L);
•Liver and kidney function: serum creatinine ≤ 1.5 times the upper limit of normal value; AST and ALT ≤ 2.5 times the upper limit of normal value (for patients with liver invasion ≤ 5 times the upper limit of normal value); total bilirubin ≤ 1.5 times the upper limit of normal value (for patients with liver invasion ≤ 3 times the upper limit of normal value);

Exclusion Criteria

•Subjects have previously received anthracyclic drug pretreatment;
•Hypersensitivity to any study drug or its components;
•Uncontrollable systemic diseases (such as advanced infection, uncontrollable hypertension, diabetes, etc.);
•Heart function and disease meet one of the following conditions: a) long QTc syndrome or QTc interval \>480 ms; b) complete left bundle branch block, grade II or III atrioventricular block; c) Serious and uncontrolled arrhythmias requiring drug treatment; d) New York Heart Association grade ≥ III; e) Cardiac ejection fraction (LVEF) lower than 50%;f) A history of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or ECG evidence of acute ischemia or active conduction system abnormalities within 6 months before recruitment.
•Active hepatitis B and C infection (positive hepatitis B virus surface antigen and more than 1x10\^3 copies/mL of hepatitis B virus DNA; more than 1x10\^3 copies/mL of hepatitis C virus RNA);
•Human immunodeficiency virus (HIV) infection (positive HIV antibody);
•Suffering from other malignant tumors in the past or at the same time (except for effectively controlled non-melanoma skin basal cell carcinoma, breast/cervix carcinoma in situ, and other malignant tumors that have been effectively controlled without treatment in the past five years);
•Suffering from primary or secondary central nervous system (CNS) lymphoma or a history of CNS lymphoma at the time of recruitment;
•Pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures;
•Other researchers judge not to Eligibility to participate in this study.

Arms & Interventions

CMOP±R

All enrolled patients. All patient who signed the consent form for participation to the study.

Intervention: CMOP±R

Outcomes

Primary Outcomes

Complete Response Rate (CRR)

Time Frame: 3 years

Response is assessed according to the 2014 lugano criteria.Percentage of participants with complete response was determined on 2014 Lugano criteria.

Secondary Outcomes

Changes in cardiac safety indicators(3 years)
Overall Response Rate (ORR)(3 years)
Progression-Free-Survival (PFS)(3 years)
Duration of Response (DOR)(3 years)
Overall survival (OS)(3 years)
Progression of disease within 2 years(POD24)(3 years)
Treatment-emergent adverse events (TEAEs)(From the initiation of the first dose to 28 days after the last dose)